J&J Subpoenaed Over Topamax, Risperdal, Natrecor

Law360, New York (March 13, 2007, 12:00 AM EDT) -- Johnson & Johnson’s marketing practices have perked the interest of attorney’s offices across the United States, three of which have issued subpoenas in the last week concerning how the company supervises the sales of its medications.

The pharmaceutical company said Monday that it had received separate subpoenas from the U.S. Attorney’s Office in Philadelphia, Boston and San Francisco.

The probes seek information about J&J’s corporate supervision and oversight of the company’s Janssen LP, Ortho-McNeil Pharmaceutical Inc. and Scios Inc. subsidiaries, especially in relation to off-label marketing....
To view the full article, register now.